Eusol Biotech Co (ROCO:6652) Debt-to-Equity : 0.02 (As of Jun. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Eusol Biotech Co Debt-to-Equity?

Eusol Biotech Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was NT$3.47 Mil. Eusol Biotech Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was NT$2.79 Mil. Eusol Biotech Co's Total Stockholders Equity for the quarter that ended in Jun. 2023 was NT$418.53 Mil. Eusol Biotech Co's debt to equity for the quarter that ended in Jun. 2023 was 0.01.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Eusol Biotech Co's Debt-to-Equity or its related term are showing as below:

ROCO:6652' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.03 Max: 0.48
Current: 0.01

During the past 9 years, the highest Debt-to-Equity Ratio of Eusol Biotech Co was 0.48. The lowest was 0.01. And the median was 0.03.

ROCO:6652's Debt-to-Equity is ranked better than
99.91% of 1069 companies
in the Biotechnology industry
Industry Median: 0.15 vs ROCO:6652: 0.01

Eusol Biotech Co Debt-to-Equity Historical Data

The historical data trend for Eusol Biotech Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eusol Biotech Co Debt-to-Equity Chart

Eusol Biotech Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.03

0.01

0.02

0.01

Eusol Biotech Co Semi-Annual Data
	Dec15	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial											0.01	-	0.02	0.02	0.01

Competitive Comparison of Eusol Biotech Co's Debt-to-Equity

For the Biotechnology subindustry, Eusol Biotech Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Eusol Biotech Co's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Eusol Biotech Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Eusol Biotech Co's Debt-to-Equity falls into.

Eusol Biotech Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Eusol Biotech Co's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.748	+	1.606)	/	400.982
	=	0.01

Eusol Biotech Co's Debt to Equity Ratio for the quarter that ended in Jun. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3.473	+	2.794)	/	418.526
	=	0.01

Eusol Biotech Co (ROCO:6652) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Eusol Biotech Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Eusol Biotech Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Eusol Biotech Co (ROCO:6652) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eusol Biotech Co Ltd (ROCO:6652) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

Minsheng E. Road, 6th Floor, No.135, Sec.3, Songshan District, Taipei, TWN, 10546

Website

http://www.eusol.com.tw

Eusol Biotech Co Ltd is a Taiwan based company that invests in developing new drugs to fulfill unmet medical needs. Its pipeline products include ES135, a recombinant human acidic fibroblast growth factor (rhFGF1) with 135 amino acids; and SM-1, a 3-in-1 capsule containing 3 commercial drugs with the sedative effect.

Eusol Biotech Co (ROCO:6652) Headlines

No Headlines